GGrantIndex
← Leaderboards

Cornell University Ithaca

Ithaca, NY

Compare ↔
$327,637,695
Total funding
946
Grants

Funding mix

By agency

NIH$328,789,512 · 944
CDC$0 · 2
FDA$0 · 1

By mechanism

R01$218,281,498 · 211
P41$38,461,644 · 525
T32$19,802,442 · 15
R37$8,315,687 · 7
P01$7,218,495 · 14
R21$5,552,563 · 20

Investigators at Cornell University Ithaca

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Largest grants

AN UNDULATOR RESOURCE FOR STRUCTURAL BIOLOGY$8,080,928
P41 · FY2001 · RR
AN UNDULATOR RESOURCE FOR STRUCTURAL BIOLOGY$3,096,715
P41 · FY2004 · RR
AN UNDULATOR RESOURCE FOR STRUCTURAL BIOLOGY$3,063,938
P41 · FY2003 · RR
Macromolecular Diffraction Resource: MacCHESS$2,765,897
P41 · FY2003 · RR
AN UNDULATOR RESOURCE FOR STRUCTURAL BIOLOGY$2,160,200
P41 · FY2005 · RR
AN UNDULATOR RESOURCE FOR STRUCTURAL BIOLOGY$2,142,302
P41 · FY2002 · RR
J.A. BAKER INST FOR ANIMAL CORE LABORATORIES$2,000,000
C06 · FY2001 · RR
Macromolecular Diffraction Resource: MacCHESS$1,869,964
P41 · FY2005 · RR
MACROMOLECULAR DIFFRACTION RESOURCE--MACCHESS$1,780,729
P41 · FY2000 · RR
MACROMOLECULAR DIFFRACTION RESOURCE--MACCHESS$1,676,930
P41 · FY2001 · RR
Macromolecular Diffraction Resource: MacCHESS$1,673,212
P41 · FY2004 · RR
MACROMOLECULAR DIFFRACTION RESOURCE--MACCHESS$1,640,067
P41 · FY2002 · RR
National Biomedical Center for Advanced ESR Technology$1,534,528
P41 · FY2001 · RR
FETAL NEUROENDOCRINOLOGY, PARTURITION AND THE MYOMETRIUM$1,495,495
P01 · FY2002 · HD
ANIMAL MODEL EVALUATION OF CANDIDATE HEPATITIS THERAPIES$1,420,336
N01 · FY2000 · AI
Environmental Approaches for Obesity Management at Dow$1,308,877
R01 · FY2004 · HL
Biotechnology Resource Digital Electro-Optical Imaging$1,292,039
P41 · FY2003 · EB
MODELS OF HEREDITY RETINAL DEGENERATION$1,291,526
R01 · FY2002 · EY
Biotechnology Resource Digital Electro-Optical Imaging$1,212,708
P41 · FY2004 · EB
MODELS OF HEREDITY RETINAL DEGENERATION$1,162,978
R01 · FY2001 · EY